New drug aims to starve prostate cancer by blocking testosterone
Disease control
Not yet recruiting
This phase 2 trial tests a drug called teverelix DP in 40 men with advanced prostate cancer. The drug works by blocking a hormone that tells the body to make testosterone, which can fuel cancer growth. The goal is to see if a specific dosing schedule can safely lower testosterone…
Phase: PHASE2 • Sponsor: Antev Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC